NCT04585711View on ClinicalTrials.gov

Pharmacokinetics and Pharmacodynamics of Biologic Drugs in Obese Patients With Arthritis

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

July 1, 2026

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions

Juvenile Idiopathic ArthritisRheumatoid ArthritisObesity

Interventions

DRUG

Etanercept Optimal dosing

Patients will receive Etanercept on an optimal dose interval over a 6-week period based on a PK/PD model.

Trial Locations (1)

27705

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

lead

Duke University

OTHER